- Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet (London, England). 2016;388(10039):73-85.
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
- Chen H, Kong Y, Yao Q, Zhang X, Fu Y, Li J, et al. Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients. Aging. 2019;11(3):885-97.
- Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003-2005: a population-based study. International journal of cancer. 2015;136(8):1921-30.
- Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047-60.
- Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet (London, England). 2011;378(9791):607-20.
- Li N, Gao W, Zhang YF, Ho M. Glypicans as Cancer Therapeutic Targets. Trends in cancer. 2018;4(11):741-54.
- Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;168:108-18.
- Filmus J, Capurro M, Rast J. Glypicans. Genome biology. 2008;9(5):224.
- Kayed H, Kleeff J, Keleg S, Jiang X, Penzel R, Giese T, et al. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. International journal of oncology. 2006;29(5):1139-48.
- Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. British journal of cancer. 2016;115(1):66-75.
- Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN oncology. 2013;2013:680136.
- Li J, Chen Y, Zhan C, Zhu J, Weng S, Dong L, et al. Glypican-1 Promotes Tumorigenesis by Regulating the PTEN/Akt/beta-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma. Digestive diseases and sciences. 2019;64(6):1493-502.
- Zhou S, O'Gorman MR, Yang F, Andresen K, Wang L. Glypican 3 as a Serum Marker for Hepatoblastoma. Scientific reports. 2017;7:45932.
- Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Journal of gastroenterology and hepatology. 2010;25(1):129-37.
- Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Archives of medical research. 2014;45(7):580-8.
- Sajorda BJ, Gonzalez-Gandolfi CX, Hathaway ER, Kalish JM. Simpson-Golabi-Behmel Syndrome Type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.
Veugelers M, Cat BD, Muyldermans SY, Reekmans G, Delande N, Frints S, et al. Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Human molecular genetics. 2000;9(9):1321-8.
Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A, Inazawa J. GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines. Journal of human genetics. 2003;48(6):331-5.
Li F, Shi W, Capurro M, Filmus J. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. The Journal of cell biology. 2011;192(4):691-704.
Okamoto K, Tokunaga K, Doi K, Fujita T, Suzuki H, Katoh T, et al. Common variation in GPC5 is associated with acquired nephrotic syndrome. Nature genetics. 2011;43(5):459-63.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23 Suppl 7:vii33-40.
Anders S, McCarthy DJ, Chen Y, Okoniewski M, Smyth GK, Huber W, et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nature protocols. 2013;8(9):1765-86.
Liao X, Huang K, Huang R, Liu X, Han C, Yu L, et al. Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. OncoTargets and therapy. 2017;10:4493-506.
The Genotype-Tissue Expression (GTEx) project. Nature genetics. 2013;45(6):580-5.
Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science (New York, NY). 2015;348(6235):648-60.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research. 2017;45(W1):W98-w102.
Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome biology. 2003;4(5):P3.
Said-Salman IH, Jebaii FA, Yusef HH, Moustafa ME. Global gene expression analysis of Escherichia coli K-12 DH5alpha after exposure to 2.4 GHz wireless fidelity radiation. Scientific reports. 2019;9(1):14425.
Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics (Oxford, England). 2005;21(16):3448-9.
Munoz-San Martin M, Reverter G, Robles-Cedeno R, Buxo M, Ortega FJ, Gomez I, et al. Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. Journal of neuroinflammation. 2019;16(1):220.
Mandelboum S, Manber Z, Elroy-Stein O, Elkon R. Recurrent functional misinterpretation of RNA-seq data caused by sample-specific gene length bias. PLoS biology. 2019;17(11):e3000481.
Li Y, Xue Z, Dong X, Liu Q, Liu Z, Li H, et al. Mitochondrial dysfunction and oxidative stress in bone marrow stromal cells induced by daunorubicin leads to DNA damage in hematopoietic cells. Free radical biology & medicine. 2019.
Frost HR. Computation and application of tissue-specific gene set weights. Bioinformatics (Oxford, England). 2018;34(17):2957-64.
Li J, Chen Y, Guo X, Zhou L, Jia Z, Peng Z, et al. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer. Journal of cellular and molecular medicine. 2017;21(5):838-47.
Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, et al. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017;32(3):295-309.e12.
Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(32):E6623-e31.
Xu N, Wu YP, Yin HB, Xue XY, Gou X. Molecular network-based identification of competing endogenous RNAs and mRNA signatures that predict survival in prostate cancer. Journal of translational medicine. 2018;16(1):274.
Valsechi MC, Oliveira AB, Conceicao AL, Stuqui B, Candido NM, Provazzi PJ, et al. GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC cancer. 2014;14:631.
Fernandez D, Guereno M, Lago Huvelle MA, Cercato M, Peters MG. Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway. Journal of cancer research and clinical oncology. 2018;144(12):2399-418.
Zheng Y, Kan M, Yu L, Niu X, Zhou D, He L, et al. GPC5 rs2352028 polymorphism and risk of lung cancer in Han Chinese. Cancer investigation. 2012;30(1):13-9.
Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. The Lancet Oncology. 2010;11(4):321-30.
Sun Y, Xu K, He M, Fan G, Lu H. Overexpression of Glypican 5 (GPC5) Inhibits Prostate Cancer Cell Proliferation and Invasion via Suppressing Sp1-Mediated EMT and Activation of Wnt/beta-Catenin Signaling. Oncology research. 2018;26(4):565-72.
Zhang C, Liu Z, Wang L, Qiao B, Du E, Li L, et al. Prognostic significance of GPC5 expression in patients with prostate cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(5):6413-8.
Mohamadkhani A, Naderi E, Sharafkhah M, Fazli HR, Moradzadeh M, Pourshams A. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. Journal of oncology. 2013;2013:738915.
Subekti DRG, Murata A, Itoh Y, Fukuchi S, Takahashi H, Kanbayashi S, et al. The Disordered Linker in p53 Participates in Nonspecific Binding to and One-Dimensional Sliding along DNA Revealed by Single-Molecule Fluorescence Measurements. Biochemistry. 2017;56(32):4134-44.
Liu Y, Shao L, Chen K, Wang Z, Wang J, Jing W, et al. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. OncoTargets and therapy. 2018;11:8371-9.
Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. International journal of oncology. 2018;52(4):1105-16.
Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P, et al. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer research. 2004;64(15):5291-300.
Zhang Y, Tang X, Shi M, Wen C, Shen B. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Biochemical and biophysical research communications. 2017;483(2):816-22.
Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W, et al. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. Journal of cellular and molecular medicine. 2018;22(1):655-67.
Yu SL, Xu LT, Qi Q, Geng YW, Chen H, Meng ZQ, et al. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Scientific reports. 2017;7:45194.
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15-36.
Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J, et al. Role of angiogenesis in pancreatic cancer biology and therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;108:1135-40.
Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, et al. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer discovery. 2019.
Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, et al. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer research. 2019;79(21):5612-25.
Hashimoto S, Furukawa S, Hashimoto A, Tsutaho A, Fukao A, Sakamura Y, et al. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(35):17450-9.
Yu Y, Liang S, Zhou Y, Li S, Li Y, Liao W. HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling. Journal of cellular biochemistry. 2019;120(3):2816-27.
Zhang H, Feng X, Zhang M, Liu A, Tian L, Bo W, et al. Long non-coding RNA CASC2 upregulates PTEN to suppress pancreatic carcinoma cell metastasis by downregulating miR-21. Cancer cell international. 2019;19:18.
Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, et al. Hypoxia-inducible factor-2alpha promotes tumor progression and has crosstalk with Wnt/beta-catenin signaling in pancreatic cancer. Molecular cancer. 2017;16(1):119.
Li W, Chen C, Zhao X, Ye H, Zhao Y, Fu Z, et al. HIF-2alpha regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. Journal of cellular and molecular medicine. 2017;21(11):2896-908.
Kong L, Liu P, Zheng M, Xue B, Liang K, Tan X. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. Epigenomics. 2020.
Yokoyama S, Hamada T, Higashi M, Matsuo K, Maemura K, Kurahara H, et al. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020.
Schneider J, Chromik AM, Uhl W, Mugge A, Bulut D. Apoptosis in esophagus and pancreas carcinoma cells induced by circulating microparticles is related to phosphatidyl serine and microparticle-associated caspases. Medical oncology (Northwood, London, England). 2012;29(2):962-9.
Sharma B, Kanwar SS. Phosphatidylserine: A cancer cell targeting biomarker. Seminars in cancer biology. 2018;52(Pt 1):17-25.
Wang H, Zhan M, Yang R, Shi Y, Liu Q, Wang J. Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. Cell cycle (Georgetown, Tex). 2018;17(17):2164-74.
Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2016;65(10):1710-20.
Lei S, He Z, Chen T, Guo X, Zeng Z, Shen Y, et al. Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway. Journal of experimental & clinical cancer research : CR. 2019;38(1):470.
Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, et al. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers. 2019;11(11).